Latest News and Events
Filter by
Selections
April 24, 2019
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
Read MoreApril 15, 2019
Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreApril 12, 2019
Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
Read MoreApril 12, 2019
Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
Read MoreMarch 29, 2019
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreMarch 18, 2019